 Osteosarcoma
"Osteosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Descriptor ID |
D012516
|
| MeSH Number(s) |
C04.557.450.565.575.650 C04.557.450.795.620
|
| Concept/Terms |
Osteosarcoma- Osteosarcoma
- Osteosarcomas
- Osteosarcoma Tumor
- Osteosarcoma Tumors
- Tumor, Osteosarcoma
- Tumors, Osteosarcoma
- Sarcoma, Osteogenic
- Osteogenic Sarcomas
- Sarcomas, Osteogenic
- Osteogenic Sarcoma
|
Below are MeSH descriptors whose meaning is more general than "Osteosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Osteosarcoma".
This graph shows the total number of publications written about "Osteosarcoma" by people in this website by year, and whether "Osteosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 2 | 0 | 2 | | 2006 | 2 | 1 | 3 | | 2007 | 2 | 0 | 2 | | 2008 | 3 | 0 | 3 | | 2009 | 3 | 2 | 5 | | 2010 | 6 | 0 | 6 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 1 | 4 | | 2013 | 4 | 0 | 4 | | 2014 | 4 | 1 | 5 | | 2015 | 6 | 1 | 7 | | 2016 | 3 | 0 | 3 | | 2017 | 3 | 1 | 4 | | 2018 | 3 | 0 | 3 | | 2019 | 3 | 1 | 4 | | 2020 | 0 | 1 | 1 | | 2021 | 5 | 0 | 5 | | 2022 | 3 | 0 | 3 | | 2023 | 3 | 0 | 3 | | 2024 | 3 | 0 | 3 | | 2025 | 4 | 0 | 4 | | 2026 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Osteosarcoma" by people in Profiles.
-
Lammers ML, Sholevar CJ, Karimzadeh M, Razmara AM, Cruz SM, Purl MC, Liu NM, Bakke D, Plagens RN, Elliott A, Sheng MK, Dongen CV, Tran T, Trinh AT, Nielsen RN, Kotamraju T, Farley LE, Iranpur KR, Mukarrama T, Gronchi A, Riedel RF, Monjazeb AM, Thorpe SW, Darrow MA, Kim J, Murphy WJ, Judge SJ, Canter RJ. Intratumoral TIGIT blockade augments antitumor responses and bypasses increased functionality of peripheral TIGIT+ NK cells in mouse and human models of bone and soft tissue sarcoma. J Immunother Cancer. 2026 Jul 22; 14(7).
-
Rebhun RB, Cruz SM, York D, Mazcko CN, Razmara AM, Patkar S, Judge SJ, Sholevar CJ, Shah RK, Zamora AE, Al-Nadaf S, Vail DM, Fan TM, Burton JH, Luker ME, Skorupski KA, Lejeune AT, Woolard K, Stewart SL, Sparger EE, Young J, Cohen-Davidyan T, Huang E, Beck JA, Murphy WJ, Kent MS, Culp WTN, LeBlanc AK, Canter RJ. Phase 2 trial (NCI-COTC030) of adjuvant inhaled recombinant human IL-15 combined with amputation and adjuvant chemotherapy in dogs with appendicular osteosarcoma. Front Immunol. 2025; 16:1672790.
-
Biermann JS, Hirbe A, Ahlawat S, Bernthal NM, Binitie O, Boles S, Brigman B, Callan AK, Cipriano C, Cranmer LD, Davis J, Donnelly E, Ferguson M, Graham A, Groundland J, Hess M, Hiniker SM, Hoover-Regan ML, Hornick JL, Jonard B, Kuechle JB, Lindskog D, Mayerson JL, McGarry SV, Morris CD, Olson D, Rose PS, Santana VM, Satcher RL, Schwartz H, Shulman RM, Thorpe SW, Wilky BA, Wustrack RL, Yoon J, Hang LE, Jones F, Sansone N, Lyons M. Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 04; 23(4).
-
Mason NJ, Selmic L, Ruple A, London CA, Barber L, Weishaar K, Perry JA, Mahoney J, Flesner B, Bryan JN, Willcox JL, Burton JH, Vail DM, Kisseberth WC, Balkman CE, McCleary-Wheeler AL, Curran KM, Leeper H, Woods JP, Mutsaers AJ, Higginbotham ML, Wouda RM, Wilson-Robles H, Dervisis N, Saba C, MacDonald-Dickinson VS, Hess PR, Cherukuri A, Rotolo A, Beck JA, Patkar S, Mazcko C, LeBlanc AK. Immunological responses and clinical outcomes in dogs with osteosarcoma receiving standard therapy and a Listeria vaccine expressing HER2. Mol Ther. 2025 04 02; 33(4):1674-1686.
-
Shi Y, Tang Y, Sun Z, Sui P, Shao Y, Wang Z, Zhang J, Gao M. Scutellarein Inhibits Osteosarcoma Growth by Targeting the TLR4/TRAF6/NF-?B Pathway. Drug Des Devel Ther. 2025; 19:51-64.
-
Dhir A, Hayashi M, Bodlak A, Oesterheld J, Loeb DM, Mascarenhas L, Isakoff MS, Sandler ES, Borinstein SC, Trucco M, Lagmay JP, Setty BA, Pratilas CA, Caywood E, Metts J, Yin H, Fridley B, Yin J, Laborde J, Reed DR, Adams DL, Wagner LM. Phase II Trial of Gemcitabine and Nab-Paclitaxel for Recurrent Osteosarcoma with Serial Monitoring Using Liquid Biopsy: A Report from the National Pediatric Cancer Foundation. Clin Cancer Res. 2024 Dec 02; 30(23):5314-5322.
-
Cao JW, Lake J, Impastato R, Chow L, Perez L, Chubb L, Kurihara J, Verneris MR, Dow S. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity. Cancer Immunol Immunother. 2024 Mar 30; 73(5):77.
-
Abrahão R, Keegan THM, Maguire FB, Li Q, Malogolowkin MH, Wong S, Thorpe SW, Carr-Asher JR, Midboe AM, Randall RL, Alvarez EM. Receipt of Guideline-Concordant Care Is Associated With Improved Survival in Patients With Osteosarcoma in California: A Population-Based Analysis. JCO Oncol Pract. 2024 08; 20(8):1064-1074.
-
Griffin KH, Thorpe SW, Sebastian A, Hum NR, Coonan TP, Sagheb IS, Loots GG, Randall RL, Leach JK. Engineered bone marrow as a clinically relevant ex vivo model for primary bone cancer research and drug screening. Proc Natl Acad Sci U S A. 2023 09 26; 120(39):e2302101120.
-
Weiser DA, Hayashi M, Applebaum MA. Breaking Up Isn't Hard to Do: Isolating Cell-free DNA Fragments in Osteosarcoma. Clin Cancer Res. 2023 06 01; 29(11):2017-2019.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|